This week, J&J JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of lawsuits ...

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

美国 FDA 肿瘤药咨询专家委员会于 9 月 26 日以 10 票赞成、2 票反对、1 票弃权的投票结果，决定默沙东的 Keytruda（帕博利珠单抗）和百时美施贵宝（BMS）的 Opdivo（纳武利尤单抗）作为一线治疗药对于生物标志物 PD-L1 检测呈阴性的胃癌患者无效。这一投票结果符合专家会成员、FDA 审评人员和申办人的共识，即当 PD-L1 ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

Summit Therapeutics (SMMT) stock traded lower as Citi downgraded the company to neutral from buy on valuation after recent surge of its shares. Read more here.

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

在其他近期新闻中，Summit Therapeutics在有希望的临床试验数据发布后受到金融公司的重点关注。Stifel将Summit Therapeutics的目标价上调至40.00美元，而H.C. Wainwright将其目标价调整至45.00美元，两家公司均维持买入评级。这些调整是基于最近的临床试验数据和在重要医学会议上的演讲，突出了Summit的药物ivonescimab的潜力。